ViroCell Biologics and AvenCell Therapeutics announce retroviral vector manufacturing collaboration to accelerate development of novel allogeneic CAR-T therapies for blood cancers
      
        
      
      
      
    
  
    
      
      ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer
      
        
      
      
      
    
  
    
      
      ViroCell Biologics Appoints Viral Vector Expert as Special Advisor
      
        
      
      
      
    
  
    
      
      ViroCell Biologics expands U.S. business development team with two new appointments
      
        
      
      
      
    
  
    
      
      ViroCell Biologics to host panel event at 2024 Cell & Gene Meeting on the Mesa
      
        
      
      
      
    
  
    
      
      ViroCell Biologics completes oversubscribed financin
      
        
      
      
      
    
  
    
      
      ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer center
      
        
      
      
      
    
  
    
      
      ViroCell to present at 2024 Cell & Gene Meeting on the Med
      
        
      
      
      
    
  
    
      
      ViroCell and Great Ormond Street Hospital poised to unlock clinical trial ‘backlog’ following MHRA manufacturing approval
      
        
      
      
      
    
  
    
      
      ViroCell expands business development team to support next phase of growth
      
        
      
      
      
    
  
    
      
      ViroCell appoints Brian Collins as CFO
      
        
      
      
      
    
  
    
      
      ViroCell accelerates 2022 momentum with appointment of John A. Dawson CBE as Chairman of the Board of Directors 
      
        
      
      
      
    
  
    
      
      ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
      
        
      
      
        Press ReleasesFlorence BuchananCDMO, UK CDMO, ViroCell, ViroCell Biologics, Great Ormond Street Hospital for Children, GOSH, NHS Foundation Trust, lentivirus vector, AAV vectors, cell and gene therapies, gene therapy, cell therapy, Zayed Centre for Research, 1L to 200L batch size, Scientific Advisory Board, John W. Hadden II, Matthew Shaw, CEO at Great Ormond Street Hospital, Great Ormond Street Hospital, Her Highness Sheikha Fatima bint Mubarak, Sheikh Zayed bin Sultan Al Nahyan, Founder of the United Arab Emirates, rare diseases, Great Ormond Street Hospital Children’s Charity, EQ, James Culverhouse, ViroCell Press Release
       
      
    
  
    
      
      ViroCell announces new Board appointments
      
        
      
      
        Press ReleasesFlorence BuchananViroCell, CDMO, UK CDMO, J. David Enloe, Martin Pule, Board of Directors, Scientific Advisory Board, gene therapy, cell therapy, viral vectors, viral vector, AAV vectors, lentivirus vectors, CGT, cell and gene therapies, Recro Pharma, Lonza, University College London, University College Hospital, Autolus Therapeutics, John W. Hadden II, Farzin Farzeneh, David Enloe, Dr. Martin Pule, ViroCell Biologics, Truell Conservation Foundation, Edmund Truell, Wellcome Trust, EQ, James Culverhouse, ViroCell Press Release, batch sizes between 1L and 200L, vector design, Daniel Truell
       
      
    
  
    
      
      ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
      
        
      
      
        Press ReleasesFlorence BuchananViroCell press release, Truell Conservation Foundation, ViroCell, Edmond Truell, John W. Hadden II, Farzin Farzaneh, Ferid Murad, Evren Alici, Jean-Pierre Bizzari, Mark Lowdell, Peter Harper, Paul G. Richardson, gene therapy, cell therapy, viral vectors, vector design, CDMO, UK CDMO, CGT, Scientfic Advisory Board, 1998 Nobel Prize in Medicine, Karolinska Institutet, French National Cancer Institute (INCa), Celgene, University College London, Royal Free London NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Welbeck Health Partners, Dana Farber Cancer Institute, Harvard Medical School, ViroCell Biologics, EQ, James Culverhouse